Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemia

Authors:
  • ASA Shah
    A Shah
  • PRP Romero
    P Romero
  • SBS Brunet
    S Brunet
  • JSJ Sierra
    J Sierra
  • ADA Domingo-Albós
    A Domingo-Albós
  • SFS Fruchtman
    S Fruchtman
  • LIL Isola
    L Isola

Abstract
Waldenstrom's disease is a lymphoproliferative disorder that is typically treated with plasmapheresis and/or alkylating agents. In young patients, other lymphoproliferative disorders have been treated with allogeneic transplantation. Two patients with aggressive Waldenstrom's disease, who progressed in spite of multi-agent chemotherapy and autologous stem cell transplantation, in one case, underwent allogeneic transplantation from their HLA-identical donors. Both remain alive with event-free survivals of more than 3, and more than 9 years, respectively. Allogeneic transplantation should be considered for young patients with Waldenstrom's disease.